TY - JOUR
T1 - Post COVID-19 syndrome with impairment of flow-mediated epicardial vasodilation and flow reserve
AU - Verma, Amanda
AU - Ramayya, Tarun
AU - Upadhyaya, Anand
AU - Valenta, Ines
AU - Lyons, Maureen
AU - Marschall, Jonas
AU - Dehdashti, Farrokh
AU - Gropler, Robert J.
AU - Woodard, Pamela K.
AU - Schindler, Thomas Hellmut
N1 - Funding Information:
This study was supported by a departmental fund from Washington University in St. Louis.
Publisher Copyright:
© 2022 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
PY - 2022/12
Y1 - 2022/12
N2 - Aims: The aim of this study is to evaluate whether post-acute sequelae of COVID-19 cardiovascular syndrome (PASC-CVS) is associated with alterations in coronary circulatory function. Materials and Methods: In individuals with PASC-CVS but without known cardiovascular risk factors (n = 23) and in healthy controls (CON, n = 23), myocardial blood flow (MBF) was assessed with 13N-ammonia and PET/CT in mL/g/min during regadenoson-stimulated hyperemia, at rest, and the global myocardial flow reserve (MFR) was calculated. MBF was also measured in the mid and mid-distal myocardium of the left ventricle (LV). The Δ longitudinal MBF gradient (hyperemia minus rest) as a reflection of an impairment of flow-mediated epicardial vasodilation, was calculated. Results: Resting MBF was significantly higher in PASC-CVS than in CON (1.29 ± 0.27 vs. 1.08 ± 0.20 ml/g/min, p ≤.024), while hyperemic MBFs did not differ significantly among groups (2.46 ± 0.53 and 2.40 ± 0.34 ml/g/min, p =.621). The MFR was significantly less in PASC-CVS than in CON (1.97 ± 0.54 vs. 2.27 ± 0.43, p ≤.031). In addition, there was a Δ longitudinal MBF gradient in PASC-CVS, not observed in CON (−0.17 ± 0.18 vs. 0.04 ± 0.11 ml/g/min, p <.0001). Conclusions: Post-acute sequelae of COVID-19 cardiovascular syndrome may be associated with an impairment of flow-mediated epicardial vasodilation, while reductions in coronary vasodilator capacity appear predominantly related to increases in resting flow in women deserving further investigations.
AB - Aims: The aim of this study is to evaluate whether post-acute sequelae of COVID-19 cardiovascular syndrome (PASC-CVS) is associated with alterations in coronary circulatory function. Materials and Methods: In individuals with PASC-CVS but without known cardiovascular risk factors (n = 23) and in healthy controls (CON, n = 23), myocardial blood flow (MBF) was assessed with 13N-ammonia and PET/CT in mL/g/min during regadenoson-stimulated hyperemia, at rest, and the global myocardial flow reserve (MFR) was calculated. MBF was also measured in the mid and mid-distal myocardium of the left ventricle (LV). The Δ longitudinal MBF gradient (hyperemia minus rest) as a reflection of an impairment of flow-mediated epicardial vasodilation, was calculated. Results: Resting MBF was significantly higher in PASC-CVS than in CON (1.29 ± 0.27 vs. 1.08 ± 0.20 ml/g/min, p ≤.024), while hyperemic MBFs did not differ significantly among groups (2.46 ± 0.53 and 2.40 ± 0.34 ml/g/min, p =.621). The MFR was significantly less in PASC-CVS than in CON (1.97 ± 0.54 vs. 2.27 ± 0.43, p ≤.031). In addition, there was a Δ longitudinal MBF gradient in PASC-CVS, not observed in CON (−0.17 ± 0.18 vs. 0.04 ± 0.11 ml/g/min, p <.0001). Conclusions: Post-acute sequelae of COVID-19 cardiovascular syndrome may be associated with an impairment of flow-mediated epicardial vasodilation, while reductions in coronary vasodilator capacity appear predominantly related to increases in resting flow in women deserving further investigations.
KW - CAD
KW - MFR
KW - PET
KW - blood flow
KW - circulation
KW - coronary endothelial function
KW - flow gradient
KW - microvascular function
KW - myocardial perfusion
UR - http://www.scopus.com/inward/record.url?scp=85138129737&partnerID=8YFLogxK
U2 - 10.1111/eci.13871
DO - 10.1111/eci.13871
M3 - Article
C2 - 36083297
AN - SCOPUS:85138129737
SN - 0014-2972
VL - 52
JO - European Journal of Clinical Investigation
JF - European Journal of Clinical Investigation
IS - 12
M1 - e13871
ER -